Received Date: 05-Feb-2015
Accepted Date: 05-Feb-2015
Article type: Letter to the Editor

Title Page

**Title:** Response to LIVint-15-00100

**Authors:** Michael J. Vinikoor,1,2 Edford Sinkala,3,4 Gilles Wandeler,5,6 and Benjamin H. Chi2,7

**Institutions:** 1Department of Medicine, University of North Carolina at Chapel Hill, North Carolina, USA; 2Centre for Infectious Disease Research in Zambia, Lusaka, Zambia; 3Department of Medicine, University of Zambia, Lusaka, Zambia; 4University Teaching Hospital, Lusaka, Zambia; 5Institute of Social and Preventive Medicine, University of Bern, Switzerland; 6Department of Infectious Diseases, University Hospital Bern, Switzerland; 7Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, North Carolina, USA

**Corresponding Author:** Dr. Michael J. Vinikoor, University of North Carolina at Chapel Hill, Centre for Infectious Disease Research in Zambia, 5032 Great North Road, P.O. Box 34681, Lusaka, Zambia; Email: mJV@med.unc.edu, Tel: +26 0211242257, Fax: +26 0211242263

**Key words:** Africa, AST-to-platelet ratio index, FIB-4, hepatitis B virus, HIV/AIDS, liver disease

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/liv.12803

This article is protected by copyright. All rights reserved.
List of abbreviations: APRI (AST-to-platelet ratio), HAT (HIV-associated thrombocytopenia), HIV (human immunodeficiency virus), HBV (hepatitis B virus), HCV (hepatitis C virus)

Conflict of interest: All other authors report no conflicts of interest.

Financial support: Research was supported by the Fogarty International Center of the U.S. National Institutes of Health (K01TW009998 and R25TW009340) and by an Ambizone-PROSPER fellowship (PZ00P3_154730) from the Swiss National Science Foundation.

Manuscript

Although AST-to-platelet ratio index (APRI) and FIB-4 have been compared with liver biopsy in patients with hepatitis C virus (HCV), hepatitis B virus (HBV), HIV/HCV co-infection, and HIV/HBV co-infection, Johannessen and Lemoine stress that they have not been validated in HIV mono-infected populations in SSA. However, this is unlikely to occur because liver biopsy does not play a role in HIV management and the procedure carries its own risks for complication. Clinicians using APRI and FIB-4 in this setting should be aware of this limitation and should interpret test results in the context of each patient’s clinical scenario.

While it elevates APRI or FIB-4 scores, HIV-associated thrombocytopenia (HAT) does not fully explain the association of these markers with mortality. In our analysis, an elevated APRI score at start of antiretroviral therapy predicted all-cause mortality — even among patients with WHO clinical stage 1 or 2 and CD4+ counts >200 cells/mm².
who were unlikely to have HAT [1]. In a sensitivity analysis not included in the primary manuscript, we replaced each patient’s platelet count with the median value of 238 x $10^9$/L. As expected, the percentage with APRI $\geq 1.5$ decreased from 5.1% to 1.9%; however, the association with mortality was similar (adjusted hazard ratio 1.62; 95% CI, 1.29-2.05).

In their letter to the editor, Johannessen and Lemoine speculate that the excess mortality experienced by patients with elevated APRI was unlikely a direct result of liver disease. Unfortunately, as is common in Africa, causes of death were not available in our large observational cohort, making this a difficult question to answer. However liver-related mortality was plausible, since HIV itself can interact with and infect multiple liver cell types [2,3] with potential clinical consequences [4] that are not fully understood, and chronic HBV, the leading cause of advanced liver disease in Africa, was not comprehensively screened for in our cohort. Further investigation is needed to better understand the contribution of liver disease to all-cause mortality among patients on HIV treatment.

Finally, it is important to note that APRI and FIB-4 independently predicted ART mortality in our analysis and may thus have a prognostic role in HIV care in SSA. As our colleagues suggest, further research is certainly needed to better define underlying biological mechanisms to determine how to incorporate their use at scale. Given the limited capacity for diagnosis and management of liver disease, however, such non-invasive metrics appear highly promising for future work.
References:


